Top 10 Predictions for US Managed Markets in 2020 & Beyond
Last year, healthcare insurers laid the groundwork for collaborations that will continue through 2020 as they transition from a focus on geographic... In DRG Blog, Market Access/ January, 2020 UnitedHealth Prefers Oncology Biosimilars Over Roche’s Herceptin, Avastin
Effective Oct. 1, 2019, UnitedHealthcare will be adding utilization criteria for Avastin and Herceptin for members under commercial and community... In DRG Blog, Market Access/ October, 2019 United States’ Plan Tackles Drug Importation
In July 2019, after four states including Florida, Vermont, Colorado, and Maine, passed bills allowing the states to create a wholesale importation... In DRG Blog, Market Access/ September, 2019 CMS Mandates Pharma to Disclose Drug Prices in TV Ads
CMS introduced a rule in May 2019 that will require pharma to provide list prices of drugs featured in TV commercials. If you are watching television... In DRG Blog, Market Access/ July, 2019 Breast Cancer Drugs Serve a New Master: The Clinical Pathway
Any company marketing a drug in the United States knows the drill: good access depends on preferred formulary placement and avoiding onerous prior... In DRG Blog, Market Access/ June, 2019 Building A Market Access Advantage During Early Stage Development
How can pharma companies build market access advantage during early stage development? The market access environment in the US has become tougher than... In DRG Blog, Market Access/ June, 2019 “Modicare” Reform Continues Push Toward Universal Coverage in India
On 23 September 2018, India’s Prime Minister Narendra Modi announced the launch of the National Health Protection Scheme or “Modicare” (PM-JAY;... In DRG Blog, Market Access/ February, 2019 71% of surveyed MCOs have outcomes-based contracts with pharma or plan to by the end of 2019
Outcomes-based contracting (OBC) is a growing value-based purchasing strategy used by U.S. healthcare payers to hold pharmaceutical... In DRG Blog, Market Access/ January, 2019 Israel’s Dental Space: Where Innovation Drives Acquisition
For decades, Israel has been well-known as a hub for innovation, producing multiple successful start-ups and large firms in numerous sectors including... In DRG Blog, Market Access, MedTech/ January, 2019 NHS Outsourcing Deal with Private Provider Set to Expand Orthopedic Market
Starting in November 2018, patients requiring elective orthopedic surgery in Plymouth, West Devon, and South East Cornwall in England will receive... In DRG Blog, Market Access, MedTech/ November, 2018 Mutual Self-Interest: Joint Venture Payer-Provider Health Plans
As large hospital systems have amassed greater power in their markets through mergers, developing regional integrated delivery networks and starting... In DRG Blog, Market Access, MedTech/ November, 2018 NASS 2018 Takeaway: Ortho Shifts to ASCs
Due to the ongoing trend toward reducing health care expenditure in the US, technological improvements that simplify and increase the safety of... In DRG Blog, Market Access, MedTech/ October, 2018 How Common is In-Office Dispensing of Oral Prostate Cancer Drugs?
The growing trend of physicians dispensing of oral oncolytics directly to patients disrupts the U.S. reimbursement system’s traditional reliance... In DRG Blog, Market Access, MedTech/ September, 2018 Renal Denervation: Will There be a Market in 5 years?
The story of renal denervation and its spectacular and shocking failure in 2014 is one of the more dramatic narratives in the medical device industry... In DRG Blog, Market Access, MedTech/ August, 2018 How will Health Insurers Control the Rising Costs of HR+/HER2- Breast Cancer Drugs?
Key finding: Confronted with the premium price of targeted therapies treating hormone receptor-positive (HR+), human epidermal growth factor receptor... In DRG Blog, Market Access, MedTech/ August, 2018 Three Drug-Pricing Controls Emerge in U.S. Market
Point-of-Sale Rebates, Copay Accumulators, and a Trump Proposal As drug prices fall under increased scrutiny, payers and regulators are targeting some... In DRG Blog, Market Access, MedTech/ June, 2018 Which Factors Will Drive Preferred Reimbursement of SLE Therapies for U.S. Payers?
Key finding: Head-to-head trial data demonstrating a drug is at least as efficacious as Benlysta – the only targeted therapy approved for systemic... In DRG Blog, Market Access, MedTech/ May, 2018 WhatsApp could prove a powerful patient engagement tool for pharma
Can mobile messaging help pharma succeed in patient engagement where past efforts have failed? In many countries, WhatsApp is becoming a verb, with... In DRG Blog, Market Access, MedTech, Digital Innovation/ May, 2018 Cleanup on Aisle 6: Seven possible results of a Walmart–Humana deal
When The Wall Street Journal first broke the news that retail titan Walmart is talking with Humana about possible acquisition, it seemed a bit far-... In DRG Blog, Market Access, MedTech, Digital Innovation/ April, 2018 Absorb BVS: Wheels Within Wheels?
DRG’s Interventional Cardiology experts take on recent news surrounding Absorb BVS The revolutionary Absorb BVS stent entered the cardiovascular... In DRG Blog, Market Access, MedTech, Digital Innovation/ May, 2017